Follow
Johan Nilvebrant
Johan Nilvebrant
Verified email at biotech.kth.se
Title
Cited by
Cited by
Year
The albumin-binding domain as a scaffold for protein engineering
J Nilvebrant, S Hober
Computational and structural biotechnology journal 6 (7), e201303009, 2013
1272013
Pneumolysin binds to the mannose receptor C type 1 (MRC-1) leading to anti-inflammatory responses and enhanced pneumococcal survival
K Subramanian, DR Neill, HA Malak, L Spelmink, S Khandaker, ...
Nature microbiology 4 (1), 62-70, 2019
1002019
ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers
J Garousi, S Lindbo, J Nilvebrant, M Åstrand, J Buijs, M Sandström, ...
Cancer research 75 (20), 4364-4371, 2015
802015
Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin
J Nilvebrant, M Åstrand, M Georgieva-Kotseva, M Björnmalm, J Löfblom, ...
PloS one 9 (8), e103094, 2014
732014
Engineering bispecificity into a single albumin-binding domain
J Nilvebrant, T Alm, S Hober, J Löfblom
PLoS One 6 (10), e25791, 2011
582011
A small bispecific protein selected for orthogonal affinity purification
T Alm, L Yderland, J Nilvebrant, A Halldin, S Hober
Biotechnology Journal 5 (6), 605-617, 2010
492010
Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma
MA Qazi, P Vora, C Venugopal, J Adams, M Singh, A Hu, M Gorelik, ...
Cancer Research 78 (17), 5023-5037, 2018
462018
Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3
J Nilvebrant, M Åstrand, J Löfblom, S Hober
Cellular and molecular life sciences 70, 3973-3985, 2013
462013
Progress and future directions with peptide-drug conjugates for targeted cancer therapy
J Lindberg, J Nilvebrant, PÅ Nygren, F Lehmann
Molecules 26 (19), 6042, 2021
442021
Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin
I Hafstrand, EC Sayitoglu, A Apavaloaei, BJ Josey, R Sun, X Han, ...
Proceedings of the National Academy of Sciences 116 (11), 5055-5060, 2019
442019
An introduction to epitope mapping
J Nilvebrant, J Rockberg
Epitope Mapping Protocols, 1-10, 2018
382018
Selection and in vitro characterization of human CD44v6‐binding antibody fragments
J Nilvebrant, G Kuku, H Björkelund, M Nestor
Biotechnology and applied biochemistry 59 (5), 367-380, 2012
372012
Protein engineering allows for mild affinity-based elution of therapeutic antibodies
S Kanje, R Venskutonytė, J Scheffel, J Nilvebrant, K Lindkvist-Petersson, ...
Journal of molecular biology 430 (18), 3427-3438, 2018
332018
Engineered autonomous human variable domains
J Nilvebrant, P M Tessier, S S Sidhu
Current pharmaceutical design 22 (43), 6527-6537, 2016
312016
CD44v6-targeted imaging of head and neck squamous cell carcinoma: antibody-based approaches
D Spiegelberg, J Nilvebrant
Contrast media & molecular imaging 2017, 2017
282017
Construction of synthetic antibody phage-display libraries
J Nilvebrant, SS Sidhu
Phage Display: Methods and Protocols, 45-60, 2018
272018
Bispecific applications of non-immunoglobulin scaffold binders
S Hober, S Lindbo, J Nilvebrant
Methods 154, 143-152, 2019
262019
In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study
AK Haylock, D Spiegelberg, J Nilvebrant, K Sandström, M Nestor
EJNMMI research 4, 1-13, 2014
212014
Purification systems based of bacterial surface proteins
T Boström, J Nilvebrant, S Hober
InTech 1, 89-136, 2012
202012
Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma
AK Haylock, D Spiegelberg, AC Mortensen, RK Selvaraju, J Nilvebrant, ...
International Journal of Oncology 48 (2), 461-470, 2016
152016
The system can't perform the operation now. Try again later.
Articles 1–20